April 2026—Thermo Fisher Scientific launched the TacroType pharmacogenetic test, a laboratory-developed test designed to help inform clinicians on dosing tacrolimus, an immunosuppressive drug for transplant recipients. Using a buccal swab sample, the test identifies a patient’s CYP3A5 genotype, which influences how quickly tacrolimus is metabolized. It is offered as a one-time pharmacogenetic assessment using rapid, qPCR-based CYP3A5 genotyping services.
Thermo Fisher Scientific, 747-494-1000